Top 5 dealmakers in licensing and joint venture for the first half of 2012

Image removed.Company: Roche/Genentech ($RHHBY)
Total: $1.37B
Partners and announced deal size: Xenon (discovery, $646M), AC Immune (preclinical, $418 million) and Savira (preclinical, $302 million)
Focus: Neurology and infectious diseases, small molecules

Image removed.

Image removed.Company: Abbott ($ABT)
Total: $1.37B
Partners: Galapagos (Phase II, $1.35B); Apricus ($16M, approved)
Focus: Autoimmune/inflammatory and genitourinary, small molecules


Image removed.Company: Merck ($MRK)
Total: $1.3 billion
Partners: Endocyte ($1B, Phase III); Ambrx ($303M, Discovery)
Focus: Cancer, small molecules and antibodies

Image removed.

Image removed.Company: Boehringer Ingelheim
Total: $815M
Partner: Forma Therapeutics
Focus: Cancer discovery, small molecules

Image removed.

Image removed.Company: Johnson & Johnson ($JNJ)
Partner: Forma Therapeutics
Total: $700M
Focus: Cancer discovery, small molecules

Image removed.

 

$(function() { $('.multistory-open').remove(); });
Read More:
Top 5 dealmakers in licensing and joint venture for the first half of 2012